GCKR P446L

GCKR P446L — The Coding Variant Behind the Glucokinase Trade-Off

Glucokinase regulatory protein (GCKRP), encoded by the GCKR gene on chromosome 2,
acts as the master brake on hepatic glucokinase (GCK), the enzyme responsible for the
liver's glucose uptake after a meal. The rs1260326 Pro446Leu variant | Proline at
position 446 is replaced by leucine in the GCKRP protein; this missense change arises
from the T allele at genomic position chr2:27508073 on the plus strand
is the functional coding variant that drives one of the most extensively replicated
metabolic findings in human GWAS: a striking trade-off between lower fasting glucose
and higher triglycerides.

This entry describes the direct coding variant. An intronic marker in the same
region, rs780094 | Intronic GCKR variant in r²=0.93 LD with rs1260326; historically
genotyped as a proxy for P446L in early GWAS arrays,
is also present in the GeneOps database and describes the same biological signal.
If you carry the T allele at rs1260326, you almost certainly also carry the T allele
at rs780094 — the two variants are nearly always co-inherited.

The Mechanism

The Pro446Leu substitution | Proline-to-leucine change at codon 446 of GCKRP, encoded
by the c.1337T allele in NM_001486.4; the T allele at genomic position 27508073 on the
GRCh38 plus strand directly alters the
regulatory domain of GCKRP in a way that impairs its response to fructose-6-phosphate
(F6P). Under normal conditions, rising intracellular F6P signals GCKRP to re-sequester
glucokinase in the nucleus, limiting further glucose phosphorylation. P446L-GKRP shows
significantly reduced sensitivity to F6P at physiological concentrations (25–500 µM) |
Biochemical assays show the P446L variant has statistically significantly reduced
inhibitory responsiveness to F6P; the variant does not affect GCKRP's response to
fructose-1-phosphate or its intrinsic inhibitory capacity.
The feedback loop is weakened, leaving glucokinase constitutively more active.

Enhanced glucokinase activity drives greater glycolytic flux through the liver.
The downstream products — malonyl-CoA and citrate — are the direct substrates for
de novo lipogenesis | The liver's synthesis of fatty acids and triglycerides from
carbohydrate precursors, which are packaged into VLDL and secreted into the
bloodstream. This mechanistic chain
explains the paradox: the same variant that improves glucose regulation simultaneously
elevates circulating triglycerides and hepatic fat.

Because rs1260326 is a missense coding variant altering a specific amino acid in GCKRP,
its functional consequences are more directly interpretable than those of the
intronic proxy rs780094. Fine-mapping across 417 kb of the GCKR locus confirmed
rs1260326 as the strongest association signal, with r²=0.93 with the previously
studied rs780094.

The Evidence

The fine-mapping study establishing rs1260326 as the likely causal variant analyzed
more than 45,000 individuals across 12 independent cohorts | Orho-Melander et al.
2008, including Scandinavian, British, Dutch, and other European-ancestry populations.
The T allele (Pro446Leu) at 34% global frequency was associated with higher fasting
triglycerides (P=3×10⁻⁵⁶), lower fasting glucose (P=1×10⁻¹³), and elevated CRP
(P=5×10⁻⁵). These associations replicate across virtually every cohort that has
examined them, making this one of the best-characterized metabolic GWAS signals
in the human genome.

The ARIC Study (n=14,889; 10,929 white, 3,960 Black) | Atherosclerosis Risk in
Communities Study; 45–64 years at baseline, prospective follow-up
quantified the per-allele effects: −1.93 mg/dl fasting glucose (P=2.3×10⁻⁷),
+0.16 mmol/l triglycerides (P=2.4×10⁻³¹), −0.45 HOMA-IR (P=2.2×10⁻⁹), and
+0.56 mg/l CRP (P=1.6×10⁻⁸) in white participants. In Black participants, TG
and insulin associations replicated (P=0.004 and P=0.002), while glucose and
HOMA-IR associations did not, suggesting some ancestry-specific modulation of
the phenotype.

A meta-analysis of five NAFLD studies (2,091 cases / 3,003 controls) | Zain et al.
2014; both Asian and non-Asian populations represented
found the T allele increases NAFLD risk with OR=1.25 (95% CI 1.14–1.36, P<0.00001).
This is the mechanistic corollary of elevated triglycerides: excess hepatic lipogenesis
deposits fat in the liver before it reaches the bloodstream as VLDL, progressively
leading to steatosis. NAFLD can develop even in T allele carriers at normal body weight.

The cardiovascular picture is nuanced. The LURIC Study | Ludwigshafen Risk and
Cardiovascular Health Study; case-control of stable CAD patients; Kozian et al.
2010 found that despite significant
elevations in plasma triglycerides and VLDL-TG, carriers of the GCKR T allele showed
no association with coronary stenosis, myocardial infarction, left ventricular
hypertrophy, or hypertension. This suggests the triglyceride particles generated by
de novo lipogenesis may be larger, more buoyant, and less atherogenic than the
small dense LDL implicated in classic atherosclerosis — but does not eliminate
the need for monitoring, particularly given the NAFLD and CRP signals.

Practical Actions

The mechanistic specificity of P446L makes dietary fructose restriction the most
targeted intervention. Because fructose enters the glycolytic pathway at
fructose-1-phosphate (bypassing the rate-limiting phosphofructokinase step), it
delivers carbon directly to the acetyl-CoA and citrate pool that feeds lipogenesis —
and GCKRP's F6P feedback mechanism cannot compensate when it is already blunted by
P446L. High-fructose loads in T allele carriers therefore produce proportionally
greater hepatic triglyceride synthesis than in CC carriers.

Omega-3 fatty acids (EPA and DHA) specifically suppress hepatic VLDL-TG secretion
and reduce de novo lipogenesis transcriptionally via PPAR-alpha and SREBP-1c pathways,
directly addressing the downstream consequence of constitutively elevated glucokinase
activity. Fasting triglyceride monitoring provides early detection of worsening lipid
profiles. Given the NAFLD OR of 1.25, periodic liver enzyme surveillance (ALT, AST,
GGT) is warranted even in the absence of other metabolic risk factors.

Relationship with rs780094 and Other Interactions

rs1260326 and rs780094 are in near-perfect linkage disequilibrium (r²=0.93) and
represent the same biological signal. Genome-wide genotyping arrays historically
assayed the intronic rs780094 more often than the coding rs1260326, so many earlier
papers report rs780094 — but both variants tag the same P446L functional change.
Users who have both variants genotyped should expect concordant results in ~93% of
cases; the rare discordance reflects the LD imperfection, not a meaningful biological
difference.

The GCK promoter variant [rs1799884 | −30G>A promoter variant in glucokinase itself;
studied in Han Chinese for additive effects on fasting glucose with GCKR variants]
operates in the same hepatic glucose-sensing regulatory complex. T allele carriers at
both loci show additive fasting glucose reductions. This interaction is relevant because
GCK and GCKR act in concert; functional variants in both could synergistically alter
the liver's glucose-sensing setpoint.

The NAFLD risk from GCKR T allele carriers is substantially compounded by co-carriage
of the PNPLA3 rs738409 G allele (an independent NAFLD risk variant), with dual
carriers showing substantially higher hepatic steatosis burden than carriers of either
variant alone. This is among the better-characterized gene-gene interactions in NAFLD
genetics and represents a clinically important compound finding.